Mallika Singh

发表

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Joshua M. Korn, Derek Y. Chiang, Tara L. Naylor, 2015, Nature Medicine.

An integrative analysis of colon cancer identifies an essential function for PRPF6 in tumor growth

M. Yaylaoglu, Zhaoshi Jiang, Grégoire Pau, 2014, Genes & development.

Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective

Mallika Singh, L. Johnson, Mallika Singh, 2006, Clinical Cancer Research.

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

Mallika Singh, N. Ferrara, 2012, Nature Biotechnology.

Anti‐VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

I. Kasman, A. Jubb, Mallika Singh, 2012, The Journal of pathology.

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

Mallika Singh, N. Ferrara, F. Shojaei, 2008, Proceedings of the National Academy of Sciences.

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous

F. Gnad, A. Daemen, Z. Modrušan, 2017, Proceedings of the National Academy of Sciences.

Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment

M. Goldsmith, Mallika Singh, R. Nichols, 2020, Cancer Research.

Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

Mallika Singh, Edward G. Lorenzana, D. Fruman, 2021, Frontiers in Oncology.

An albumin-butyrylcholinesterase for cocaine toxicity and addiction: catalytic and pharmacokinetic properties.

S. Brimijoin, Mallika Singh, Yang Gao, 2008, Chemico-biological interactions.

Repressor of the Murine Immunoglobulin Heavy-Chain 3'ac Enhancer at Early Stages of B-Cell Differentiation

Mallika Singh, B. Birshtein, 2003 .

Concerted repression of an immunoglobulin heavy-chain enhancer , 3 ' aE ( hs 1 , 2 )

Mallika Singh, B. Birshtein, 2005 .

Development of a long-acting insulin analog using albumin fusion technology.

O. Pickeral, Mallika Singh, S. Ruben, 2005, Diabetes.

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

I. Kasman, O. Rosen, Mallika Singh, 2010, Clinical Cancer Research.

An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis

Mallika Singh, S. Ruben, A. Duttaroy, 2003, Nature Biotechnology.

Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.

Erkki Ruoslahti, Masahiro Inoue, Jason A Hoffman, 2003, Cancer cell.

Correction: Mutator Suppression and Escape from Replication Error–Induced Extinction in Yeast

B. Preston, Mallika Singh, M. Ogawa, 2011, PLoS Genetics.

Mutator Suppression and Escape from Replication Error–Induced Extinction in Yeast

B. Preston, Mallika Singh, M. Ogawa, 2011, PLoS genetics.

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

Mallika Singh, W. Forrest, H. Koeppen, 2010, Nature Biotechnology.

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapy

D. Felsher, Mallika Singh, A. Gill, 2022, bioRxiv.

Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer

Mallika Singh, J. Eastham‐Anderson, R. Vij, 2015, Science Translational Medicine.

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis

Minhong Yan, I. Kasman, Mallika Singh, 2006, Nature.

Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer

Mallika Singh, W. Forrest, K. Hoeflich, 2014, Molecular Cancer Therapeutics.

Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes.

D. Hanahan, K. Chin, J. Gray, 2004, Cancer cell.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

G. Kiss, M. Goldsmith, Mallika Singh, 2017, bioRxiv.

Mouse tumour models to guide drug development and identify resistance mechanisms

Mallika Singh, N. Pryer, M. Das Thakur, 2014, The Journal of pathology.

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Mallika Singh, A. Gill, W. C. Gustafson, 2022, Cancer Research.

BSAP (Pax5)-Importin α1 (Rch1) Interaction Identifies a Nuclear Localization Sequence*

Mallika Singh, A. Emelyanov, B. Birshtein, 2000, The Journal of Biological Chemistry.

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

G. Kiss, N. Rosen, Mallika Singh, 2021, Nature Chemical Biology.

Abstract 4172: Activation of AR signaling by mifepristone enhances prostate cancer growth and impairs enzalutamide response

Mallika Singh, E. Jackson, J. Medina, 2017 .

Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes.

Mallika Singh, L. Johnson, Christopher L Murriel, 2012, Cancer research.

Crystal Structure of BMP-9 and Functional Interactions with Pro-region and Receptors*

Mallika Singh, V. Roschke, S. Choe, 2005, Journal of Biological Chemistry.

Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor Immunity

M. Goldsmith, Mallika Singh, E. Quintana, 2020, Frontiers in Immunology.

Abstract 1261: A next generation tri-complex KRASG12C(ON) inhibitor directly targets the active, GTP-bound state of mutant RAS and may overcome resistance to KRASG12C(OFF) inhibition

Mallika Singh, R. Nichols, A. Gill, 2021, Experimental and Molecular Therapeutics.

Proapoptotic activation of death receptor 5 on tumor endothelial cells disrupts the vasculature and reduces tumor growth.

A. Yang, Mallika Singh, R. Weimer, 2012, Cancer cell.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

P. Hegde, I. Kasman, A. Jubb, 2013, The Journal of clinical investigation.

Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies

Matthew J. Brauer, C. James, P. Hegde, 2013, Clinical Cancer Research.

Mouse DNA polymerase ε gene (Pole) maps to Chromosome 5

R. Goldsby, B. Preston, Mallika Singh, 2009, Mammalian Genome.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

W. Sellers, M. P. Dillon, Y. Mishina, 2020, Journal of medicinal chemistry.

Defective DNA polymerase-δ proofreading causes cancer susceptibility in mice

R. Goldsby, B. Preston, Mallika Singh, 2001, Nature Medicine.

Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers

Mallika Singh, A. Gill, J. Knox, 2022, Cancer Research.

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

G. Wang, G. Kiss, Mallika Singh, 2022, Journal of medicinal chemistry.

Abstract 3596: RM-036, a first-in-class, orally-bioavailable, Tri-Complex covalent KRASG12D(ON) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models

Mallika Singh, A. Gill, C. Weller, 2022, Cancer Research.

Abstract 3598: A first-in-class tri-complex KRASG13C(ON) inhibitor validates therapeutic targeting of KRASG13Cand drives tumor regressions in preclinical models

Mallika Singh, A. Gill, J. Knox, 2022, Cancer Research.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

M. P. Dillon, Mallika Singh, E. Lees, 2017, Journal of medicinal chemistry.

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Joshua M. Korn, W. Sellers, F. Shen, 2018, Cancer research.

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Mallika Singh, R. Nichols, Y. Pourfarjam, 2023, Science.

Mouse DNA polymerase δ gene (Pold1) maps to Chromosome 7

R. Goldsby, B. Preston, Mallika Singh, 2009, Mammalian Genome.

Development of a dihydroartemisinin-resistant Molt-4 leukemia cell line.

Mallika Singh, Narendra Singh, Henry C. Lai, 2014, Anticancer research.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

P. Hegde, I. Kasman, A. Jubb, 2013, The Journal of clinical investigation.

Abstract 3295: Inhibiting vascular morphogenesis in tumors: EGFL7 as a novel therapeutic target

I. Kasman, Mallika Singh, R. Carano, 2011 .

A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer

Sourav Bandyopadhyay, Mallika Singh, H. Goodarzi, 2023, Oncogene.

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

G. Kiss, M. Goldsmith, Mallika Singh, 2018, Nature Cell Biology.

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1

J. Asara, Mallika Singh, E. Henske, 2023, Journal of Clinical Investigation.